The cancer tissue page shows antibody staining in 20 different cancers. The overall cancer tissue staining statistics shows the fraction of patient samples with strong, moderate, weak or no staining (as described by the color-coding scale in the box to the right), using all the available antibodies to the protein targets encoded by this gene. The assay and annotation is described here.
The cancers can be ordered histologically or alphabetically.
For each cancer, the staining for each available antibody is reported as the fraction of samples with strong, moderate, weak or no staining (as described by the color-coding scale in the box to the right). The lenght of the bar represents the number of patient samples analysed (max=12 patients). By clicking on a cancer tissue, the detailed staining data for that cancer is available, including annotated images.
At the bottom of this page, a summary for the cancer staining for each antibody is given, together with the immunohistochemistry validation score for that antibody.
Most of the malignant tissues displayed weak to moderate cytoplasmic positivity. Most malignant lymphomas and many cases of squamous cell carcinomas and renal cancers were negative.
Malignant lymphomas, colorectal, breast and endometrial cancers displayed moderate cytoplasmic staining with additional membranous positivity in a few cases. Remaining malignancies were negative or weakly stained.
Moderate nuclear staining was seen in a few to several cases of most malignancies. The remaining malignant cells were weakly stained or negative.
A few cases of malignant melanoma, lung, breast, ovarian, urothelial, stomach, pancreatic and liver cancers displayed moderate cytoplasmic staining with membranous positivity in occasional cases. Rare cases of lung, urothelial and breast cancer were strongly positive. Remaining cancer tissues were weakly stained or negative.
Validation
Two (or more) antibodies yielding dissimilar staining patterns which are partly consistent with gene/protein characterization data or consistent with limited gene/protein characterization data
Two (or more) antibodies yielding dissimilar staining patterns which are partly consistent with gene/protein characterization data or consistent with limited gene/protein characterization data
Two (or more) antibodies yielding dissimilar staining patterns which are consistent with available gene/protein characterization data
The multi-targeting antibody yielding a staining pattern partly consistent with gene/protein characterization data or consistent with limited gene/protein characterization data for all of the genes
